Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Survival analysis and time to next treatment.


  1. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759–69.

    Article  CAS  Google Scholar 

  2. Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57–73.

    Article  CAS  Google Scholar 

  3. Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D’Agostino M, et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018;32:1697–712.

    Article  Google Scholar 

  4. Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131:301–10.

    Article  CAS  Google Scholar 

  5. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281–90.

    Article  CAS  Google Scholar 

  6. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–25.

    Article  CAS  Google Scholar 

  7. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.

    Article  CAS  Google Scholar 

  8. Moreau P, Kolb B, Attal M, Caillot D, Benboubker L, Tiab M, et al. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood. 2015;125:3100–4.

    Article  CAS  Google Scholar 

  9. Leleu X, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, et al. Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03). Blood. 2015;25:4224–30.

    Google Scholar 

  10. Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133:1953–63.

    Article  CAS  Google Scholar 

  11. Durie BGM, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.

    Article  CAS  Google Scholar 

Download references


The authors wish to thank the patients and families, the centers that participated to the study, the CRC teams in the centers and the IFM teams. The authors wish to thank the sponsor Lille academic hospital, the DRC: Dib Malek, Chanaz Louni, Axel Duquenoy, Angeline Dautremepuis; the biochemistry platform: Brigitte Onraed, Suzanna Schraen; Lille hospital central pharmacy: Sylvie Brice, Beatrice Thielemans; the statistical analysis platform: Alain Duhamel, François Machuron, Julien Labreuche, Maéva Kyheng; and the pharmacovigilance platform: Thavarak Ouk. A special thanks to Dr Claire Mathiot, the administrative director of IFM for decades and at the time of that study. The IFM wish to thank and honor Dr Brigitte Kolb who sadly passed away before the paper was published.


The study was supported by Amgen for funding and drug supply of carfilzomib.

Author information

Authors and Affiliations




Conception and design: XL, TF. Conduction of Trial: XL, TF, and MOP. Collection and assembly of data: AB, SG, CGM, VR, LK, BK, MT, CA, NM, JVM, PB, PL, AP, MR, AJ, KBM, MLC, JF, PR, AS, FO, LV, SC, FK, SR, OD, CHK, JF, OF, DRW, JCE, VD, EV, PM, HAL, CH, TF, and XL. Data analysis and interpretation: XL, AB, MK, and AD. Paper writing: XL, AB, and MK.

Corresponding author

Correspondence to Xavier Leleu.

Ethics declarations

Competing interests

XL honorarium from BMS Celgene, Janssen, Merck, Takeda, Amgen, Sanofi, Novartis, Roche, Karyopharm, Oncopeptide. LK honorarium from Janssen, Amgen, Celgene, advisory committees for Janssen, Amgen, Celgene, travel support from Janssen, Amgen. MR consultancy for Amgen, Celgene, Takeda. KBM consultancy and honorarium from Celgene, Janssen, Amgen, Takeda. OD honorarium from Celgene, Janssen, Takeda, Amgen. MA consultancy and research funding from Amgen, Celgene, Janssen, consultancy for Sanofi. PM honorarium and advisory committees for Amgen, Celgene, Janssen, Abbvie, Takeda, and speakers bureau for Amgen, Celgene, Janssen, Abbvie. HAL honorarium and advisory committees for Amgen, Celgene, Janssen, Sanofi, Abbvie, Takeda, research funding from Amgen, Celgene, Sanofi, Takeda. CH honorarium from Celgene, Janssen, Amgen, Takeda, research funding from Celgene, Janssen. TF honorarium and advisory committees and speakers bureau for Celgene, Janssen, Takeda, Amgen, Sanofi, Karyopharm, Oncopeptides.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bobin, A., Kyheng, M., Guidez, S. et al. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma. Leukemia 36, 881–884 (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links